Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Silvan Tuerkcan
CJ
Silvan Tuerkcan
Citizens JMP
Wall Street Analyst
★★★★☆
#647
on 13Foresight · ranked by our own returns
67%
Success Rate
+53.5%
Average Return
14 of 21 calls profitable · +37.6% vs benchmark
📈 Across the calls we could measure, roughly 67% of Silvan Tuerkcan's ratings turned a profit when each position was held for 1 year — averaging +53.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

43 Buy 5 Hold 0 Sell
Silvan's Stock Coverage 21 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
RLAY
Relay Therapeutics
 May 20, 2026 BUY Strong Buy
+28.3% avg upside
19 analysts
$21.00
31.95% Upside
 +21.7%
ENGN
enGene Holdings
 May 08, 2026 HOLD Buy
+477.8% avg upside
13 analysts
 — +16.7%
NTLA
Intellia Therapeutics
 Apr 28, 2026 BUY Buy
+158.2% avg upside
37 analysts
$30.00
98.23% Upside
 -8.3%
CRSP
Crispr Therapeutics AG
 Jan 30, 2026 BUY Buy
+41.5% avg upside
41 analysts
$80.00
50.32% Upside
 +4.1%
NUVB
Nuvation Bio
 Nov 20, 2025 BUY Strong Buy
+140.8% avg upside
15 analysts
$10.00
85.81% Upside
 -24.0%
TSHA
Taysha Gene Therapies
 Nov 05, 2025 BUY Strong Buy
+108.8% avg upside
21 analysts
$8.00
27.70% Upside
 +53.6%
BNTC
Benitec Biopharma
 Nov 04, 2025 BUY Strong Buy
+122.8% avg upside
13 analysts
$22.00
85.17% Upside
 -26.9%
FHTX
Foghorn Therapeutics
 Oct 31, 2025 BUY Strong Buy
+191.1% avg upside
17 analysts
$9.00
121.67% Upside
 -2.9%
IDYA
IDEAYA Biosciences
 Oct 13, 2025 BUY Strong Buy
+55.3% avg upside
29 analysts
$45.00
45.56% Upside
 +13.7%
JSPR
Jasper Therapeutics
 Sep 22, 2025 BUY Strong Buy
+6180.1% avg upside
17 analysts
$6.00
1165.08% Upside
 -81.5%
ACRV
Acrivon Therapeutics, Inc.
 Sep 17, 2025 BUY Strong Buy
+847.5% avg upside
13 analysts
$13.00
758.03% Upside
 +13.5%
SLDB
Solid Biosciences
 Sep 12, 2025 BUY Strong Buy
+112.8% avg upside
23 analysts
$15.00
98.99% Upside
 +28.4%
MGNX
MacroGenics
 Aug 15, 2025 HOLD Buy
+341.3% avg upside
25 analysts
 — +163.3%
EXEL
Exelixis
 Jul 29, 2025 BUY Strong Buy
-21.4% avg upside
33 analysts
$50.00
2.75% Downside
 +43.8%
PRME
Prime Medicine, Inc.
 Jun 18, 2025 BUY Strong Buy
+215.8% avg upside
16 analysts
$6.00
93.00% Upside
 +70.0%
CNTX
Context Therapeutics
 Jun 03, 2025 BUY Strong Buy
+917.0% avg upside
12 analysts
$4.00
557.39% Upside
 +272.4%
VOR
Vor Biopharma
 May 09, 2025 HOLD Buy
+190.9% avg upside
17 analysts
 — +460.9%
CLLS
Cellectis SA
 Mar 14, 2025 BUY Strong Buy
+551.9% avg upside
16 analysts
$6.00
96.66% Upside
 +175.8%
NTBLQ
Notable Labs
 Dec 27, 2024 HOLD Buy
+809999900.0% avg upside
12 analysts
 — -99.8%
TWO
Two Harbors
 Jan 26, 2023 BUY Buy
+8.3% avg upside
15 analysts
$18.00
45.16% Upside
 -12.4%
EDIT
Editas Medicine
 May 07, 2020 HOLD Buy
+434.5% avg upside
33 analysts
 — +41.5%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Silvan Tuerkcan — Frequently Asked Questions
How accurate are Silvan Tuerkcan's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Silvan's ratings were profitable over a one-year hold, with an average return of +53.5% per rating, or +37.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Silvan ranked on 13Foresight?
Silvan Tuerkcan is currently ranked #647 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Silvan cover?
Silvan most recently has ratings on RLAY, ENGN, NTLA, CRSP, NUVB, TSHA, BNTC, FHTX, IDYA, JSPR, ACRV, SLDB and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.